Intellia Therapeutics, Inc. (NTLA)
12.26
+0.14
(+1.16%)
USD |
NASDAQ |
Oct 02, 16:00
12.16
-0.10
(-0.82%)
After-Hours: 20:00
Intellia Therapeutics Enterprise Value : 1.352B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.352B |
| October 01, 2026 | 1.333B |
| September 30, 2026 | 1.324B |
| September 29, 2026 | 1.320B |
| September 28, 2026 | 1.235B |
| September 25, 2026 | 1.281B |
| September 24, 2026 | 1.338B |
| September 23, 2026 | 1.362B |
| September 22, 2026 | 1.412B |
| September 21, 2026 | 1.347B |
| September 18, 2026 | 1.335B |
| September 17, 2026 | 1.352B |
| September 16, 2026 | 1.244B |
| September 15, 2026 | 1.226B |
| September 14, 2026 | 1.298B |
| September 11, 2026 | 1.279B |
| September 10, 2026 | 1.306B |
| September 09, 2026 | 1.345B |
| September 08, 2026 | 1.419B |
| September 04, 2026 | 1.419B |
| September 03, 2026 | 1.411B |
| September 02, 2026 | 1.422B |
| September 01, 2026 | 1.412B |
| August 31, 2026 | 1.418B |
| August 28, 2026 | 1.438B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.471B |
| August 26, 2026 | 1.482B |
| August 25, 2026 | 1.527B |
| August 24, 2026 | 1.394B |
| August 21, 2026 | 1.433B |
| August 20, 2026 | 1.377B |
| August 19, 2026 | 1.495B |
| August 18, 2026 | 1.260B |
| August 17, 2026 | 1.328B |
| August 14, 2026 | 1.303B |
| August 13, 2026 | 1.292B |
| August 12, 2026 | 1.328B |
| August 11, 2026 | 1.319B |
| August 10, 2026 | 1.319B |
| August 07, 2026 | 1.307B |
| August 06, 2026 | 1.209B |
| August 05, 2026 | 1.172B |
| August 04, 2026 | 1.221B |
| August 03, 2026 | 1.144B |
| July 31, 2026 | 1.131B |
| July 30, 2026 | 1.188B |
| July 29, 2026 | 1.148B |
| July 28, 2026 | 1.160B |
| July 27, 2026 | 1.130B |
| July 24, 2026 | 1.138B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Beam Therapeutics, Inc. | 1.624B |
| Twist Bioscience Corp. | 11.75B |
| Prime Medicine, Inc. | 556.00M |
| Moderna, Inc. | 71.96B |
| Q32 Bio, Inc. | 94.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -106.63M |
| Revenue (Quarterly) | 7.659M |
| Total Expenses (Quarterly) | 114.29M |
| EPS Diluted (Quarterly) | -0.7989 |
| Gross Profit Margin (Quarterly) | 72.58% |
| Profit Margin (Quarterly) | -1.39K% |
| Earnings Yield | -27.38% |
| Normalized Earnings Yield | -27.35 |